STOCK TITAN

Emergent BioSolutions Reports First Quarter 2024 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Emergent BioSolutions Inc. reported first-quarter 2024 financial results, with total revenues of $300.4 million, a net income of $9.0 million, and adjusted EBITDA of $66.9 million. The company saw significant growth in all key products, leading to improvement in debt position, reduction in operating expenses, and strengthened financial flexibility. The transformation process is ongoing, aimed at enabling faster, farther, and more nimble operations to address evolving public health threats. Financial highlights include increased total revenues by 83%, net income per diluted share by 105%, and adjusted EBITDA by 166% compared to the same period last year.

Positive
  • Emergent BioSolutions Inc. reported strong financial performance with a significant increase in total revenues, net income, and adjusted EBITDA compared to the previous year.

  • The company saw growth across all key products, leading to improved debt position, reduced operating expenses, and strengthened financial flexibility.

  • Appointed industry leader Joseph C. Papa as the new President, CEO, and Director, demonstrating a strategic move to enhance leadership and drive growth.

  • Secured a procurement contract valued up to $235.8 million to supply BioThrax® to the U.S. Department of Defense, showcasing steady government contract wins.

Negative
  • Cost of services increased by 41%, impacting the gross margin negatively, highlighting the need for cost management in the services segment.

  • Research and development expenses decreased by 63%, indicating possible reduction in innovation and development activities within the company.

  • Selling, general, and administrative expenses decreased by 16%, reflecting possible cuts in compensation and other costs, which could impact operational efficiency.

  • First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance range
  • First Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 million
  • Updates FY 2024 guidance

GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024.

"We delivered a strong quarter with growth across all our key products,” said Joe Papa, President and CEO at Emergent. “We also took significant actions to improve our debt position, reduce operating expenses and strengthen our financial flexibility. Emergent's transformation will not happen overnight. The actions we are implementing today, combined with the assets Emergent possesses, will enable us to move faster, reach farther and be more nimble. The public health threats we collectively face are changing, and so is Emergent.”

FINANCIAL HIGHLIGHTS (1)

Q1 2024 vs. Q1 2023

($ in millions, except per share amounts)Q1 2024Q1 2023% Change
Total Revenues$300.4 $164.3 83%
Net Income (Loss)$9.0 $(186.2)105%
Net Income (Loss) per Diluted Share$0.17 $(3.71)105%
Adjusted Net Income (Loss) (2)$31.1 $(163.5)119%
Adjusted Net Income (Loss) per Diluted Share (2)$0.59 $(3.26)118%
Adjusted EBITDA (2)$66.9 $(101.5)166%
Total Segment Gross Margin % (2) 51% 3% 
Total Segment Adjusted Gross Margin % (2) 51% 5% 
        

SELECT Q1 2024 AND OTHER RECENT BUSINESS UPDATES

  • Appointed industry leader Joseph C. Papa as new President, CEO and Director
  • Was awarded procurement contract valued up to $235.8 Million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
  • Received "no action indicated" (NAI) status for Baltimore Bayview Manufacturing Facility
  • Continued progress on strengthening our fundamentals with key focus on our Medical Countermeasure (“MCM”) and NARCAN® products
  • Amended our senior secured credit facility

FIRST QUARTER 2024 FINANCIAL PERFORMANCE (1)

Revenues

The Company uses the following categories in discussing product/service level revenues:

  • NARCAN® — comprises contributions from NARCAN® Nasal Spray
  • Other Commercial Products - comprises contributions from Vaxchora® and Vivotif®, which we sold to Bavarian Nordic as part of our travel health business in May 2023
  • Anthrax MCM — comprises potential contributions from CYFENDUS®, previously known as AV7909, BioThrax®, Anthrasil® and Raxibacumab
  • Smallpox MCM — comprises potential contributions from ACAM2000®, VIGIV and TEMBEXA®
  • Other Products — comprises potential contributions from BAT®, RSDL® and Trobigard®
  • Bioservices — comprises service and lease revenues from the Bioservices business
    
($ in millions)Q1 2024Q1 2023% Change
Product sales, net (3):   
NARCAN®$118.5$100.418%
Other Commercial Products  5.8(100)%
Anthrax MCM 55.9 21.9155%
Smallpox MCM 50.2 7.2*
Other Products 49.3 8.1*
Total Product sales, net$273.9$143.491%
    
Bioservices:   
Services$18.3$12.645%
Leases 0.2 1.8(89) %
Total Bioservices revenues$18.5$14.428%
    
Contracts and grants$8.0$6.523%
    
Total revenues$300.4$164.383%
    
* % change is greater than +/- 200%   


Products Revenue, net

NARCAN®

For Q1 2024, revenues from NARCAN® (naloxone HCl) Nasal Spray increased $18.1 million, or 18%, as compared with Q1 2023. The increase was primarily driven by higher branded NARCAN® sales to U.S. public interest channels and sales of OTC NARCAN®, partially offset by lower Canadian retail sales of branded NARCAN®.

Other Commercial Products

For Q1 2024, revenues from Other Commercial Products decreased $5.8 million, or 100%, as compared with Q1 2023. The decrease was due to no sales of our Vaxchora® and Vivotif® products during the current quarter, which we sold to Bavarian Nordic as part of our travel health business in May 2023.

Anthrax MCM

For Q1 2024, revenues from Anthrax MCM increased $34.0 million, or 155%, as compared with Q1 2023. The increase reflects the impact of timing of sales related to CYFENDUS® and BioThrax®. Anthrax vaccine product sales are primarily made under annual purchase options exercised by the USG. Fluctuations in revenues result from the timing of the exercise of annual purchase options, the timing of USG purchases, the availability of governmental funding and Company delivery of orders that follow.

Smallpox MCM

For Q1 2024, revenues from Smallpox MCM increased $43.0 million as compared with Q1 2023. The increase was primarily due to higher VIGIV and ACAM2000® sales due to timing. Fluctuations in revenues from Smallpox MCM result from the timing of the exercise of annual purchase options in the existing procurement contracts, the timing of USG purchases, the availability of governmental funding and Company delivery of orders that follow.

Other Products

For Q1 2024, revenues from other product sales increased $41.2 million as compared with Q1 2023. The increase was primarily due to higher BAT and RSDL® product sales due to timing.

Bioservices Revenues

Services

For Q1 2024, revenues from Bioservices services increased $5.7 million, or 45%, as compared with Q1 2023. The increase was driven by an increase in production at the Company's Camden facility, partially offset by decreases in production at the Company’s Canton and Winnipeg facilities.

Leases

For Q1 2024, revenues from Bioservices leases decreased $1.6 million, or 89%, as compared with Q1 2023. The decrease was related to the completion of a lease for a Bioservices customer at our Canton facility.

Contracts and Grants

For Q1 2024, revenues from contracts and grants increased $1.5 million, or 23%, as compared with Q1 2023. The increase was due to development work in connection with EbangaTM, partially offset by the close out of other development initiatives.

Operating Expenses

($ in millions)Q1 2024Q1 2023% Change
Cost of Commercial product sales$52.1$45.814%
Cost of MCM product sales 62.2 55.412%
Cost of Bioservices 30.3 51.7(41 )%
Research and development (“R&D”) 15.1 40.7(63 )%
Selling, general and administrative (“SG&A”) 84.7 101.3(16 )%
Amortization of intangible assets 16.2 17.0(5)%
Total operating expenses$260.6$311.9(16 )%
       

Cost of Commercial Product Sales

For Q1 2024, cost of Commercial product sales increased $6.3 million, or 14%, as compared with Q1 2023. The increase was primarily due to higher sales of OTC NARCAN®, which launched during the third quarter of 2023, partially offset by lower Canadian retail sales of branded NARCAN®.

Cost of MCM Product Sales

For Q1 2024, cost of MCM product sales increased $6.8 million, or 12%, as compared with Q1 2023. The increase was primarily due to higher sales of BAT®, VIGIV, BioThrax® and CYFENDUS®, partially offset by a decrease in shutdown costs.

Cost of Bioservices

For Q1 2024, cost of Bioservices decreased $21.4 million, or 41%, as compared with Q1 2023. The decrease was primarily due to a reduction in overhead costs at the Company’s Camden and Bayview facilities, coupled with no production activities at the Company’s Canton facility. The decrease in costs at the Camden facility was partially offset by increases in production activity following the remediation of matters related to the FDA's warning letter, which was closed out in October 2023.

Research and Development Expenses

For Q1 2024, R&D expenses decreased $25.6 million, or 63%, as compared with Q1 2023. The decrease was primarily due to the sale of our development program for CHIKV VLP to Bavarian Nordic and reduction in related overhead costs, as well as a reduction in overhead costs driven by the headcount reductions as a result of restructuring. The decrease was partially offset by an increase in expense related to development activities for EbangaTM.

Selling, General and Administrative Expenses

For Q1 2024, SG&A expenses decreased $16.6 million, or 16%, as compared with Q1 2023. The decrease was primarily due to decreases in compensation and other employee costs as a result of the restructuring initiatives that began during the first quarter of 2023 and a reduction in professional services fees related to general corporate initiatives in the prior year, including organizational transformation consulting fees. These decreases were partially offset by an increase in marketing expenses related to the launch of OTC NARCAN® and higher legal services fees.

ADDITIONAL FINANCIAL INFORMATION (1)

Capital Expenditures

($ in millions)Q1 2024Q1 2023% Change 
Capital expenditures$10.8 $15.1 (28 )%
Capital expenditures as a % of total revenues 4% 9%  
         

For Q1 2024, capital expenditures decreased largely due to lower product development activities across the Company’s facilities.

SEGMENT INFORMATION

In the fourth quarter of 2023, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting process. The Company now manages the business with a focus on three reportable segments: (1) a Commercial Products segment consisting of our NARCAN® and other commercial products which were sold as part of our travel health business in the second quarter of 2023; (2) a MCM Products segment consisting of the Anthrax - MCM, Smallpox - MCM and Other products and (3) a services segment (“Services”) consisting of our Bioservices. The Company evaluates the performance of these reportable segments based on revenue and segment adjusted gross margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales, but does not include inter-segment services. The Company does not allocate contracts and grants, R&D, SG&A, amortization of intangible assets, interest and other income (expense) or taxes to its evaluation of the performance of these segments.

FIRST QUARTER 2024 SEGMENT RESULTS

($ in millions)Commercial Products
Quarter Ended March 31,
 2024  2023 $ Change% Change
Revenues$118.5 $106.2 $12.312%
Cost of sales 52.1  45.8  6.314%
Gross margin **$66.4 $60.4 $6.010%
Gross margin % ** 56% 57%  
     
Segment adjusted gross margin (2)$66.4 $60.4 $6.010%
Segment adjusted gross margin % (2) 56% 57%  
     
** Gross margin is calculated as revenues less cost of sales. Gross margin % is calculated as gross margin divided by revenues.


Commercial Products gross margin increased $6.0 million, or 10%, to $66.4 million in the quarter, as compared with $60.4 million in the prior year quarter. Commercial Products gross margin percentage decreased 1 percentage point to 56% for the quarter ended March 31, 2024. The decrease was largely due to the higher sales of OTC NARCAN® and lower branded NARCAN® sales. Commercial Products segment adjusted gross margin is consistent with gross margin.

($ in millions)MCM Products
Quarter Ended March 31,
 2024  2023 $ Change% Change
Revenues$155.4 $37.2 $118.2 *
Cost of sales 62.2  55.4  6.8 12%
Gross margin **$93.2 $(18.2)$111.4 *
Gross margin % ** 60%(49) %  
Add back:    
Changes in fair value of contingent consideration$0.5 $0.3 $0.2 67%
Restructuring costs (0.1) 2.0  (2.1)(105)          %
Segment adjusted gross margin (2)$93.6 $(15.9)$109.5 *
Segment adjusted gross margin % (2) 60%(43) %  
     
* % change is greater than +/- 200%    
** Gross margin is calculated as revenues less cost of sales. Gross margin % is calculated as gross margin divided by revenues.


MCM Products gross margin increased $111.4 million to $93.2 million in the quarter, as compared with $(18.2) million in the prior year quarter. MCM Products gross margin percentage increased 109 percentage points to 60% for the quarter ended March 31, 2024. The increase was primarily due to a favorable sales mix which was weighted more heavily towards higher margin products and a decrease in shutdown costs compared to the prior quarter. MCM Product segment adjusted gross margin in the current year period excludes the impact of non-cash

FAQ

What were Emergent BioSolutions' total revenues for the first quarter of 2024?

Emergent BioSolutions reported total revenues of $300.4 million for the first quarter of 2024.

Who is the President and CEO of Emergent BioSolutions?

Joseph C. Papa serves as the President and CEO of Emergent BioSolutions.

What is Emergent BioSolutions' stock symbol?

Emergent BioSolutions' stock symbol is EBS.

What actions did Emergent BioSolutions take to improve financial flexibility?

Emergent BioSolutions took significant actions to improve their debt position, reduce operating expenses, and strengthen financial flexibility.

What contract did Emergent BioSolutions secure with the U.S. Department of Defense?

Emergent BioSolutions secured a procurement contract valued up to $235.8 million to supply BioThrax® to the U.S. Department of Defense.

Emergent BioSolutions Inc.

NYSE:EBS

EBS Rankings

EBS Latest News

EBS Stock Data

586.90M
52.40M
2.16%
69.96%
12.08%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
GAITHERSBURG